Literature DB >> 12105244

Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling.

Oliver Gross1, Kai-Olaf Netzer, Romy Lambrecht, Stefan Seibold, Manfred Weber.   

Abstract

BACKGROUND: Alport syndrome (AS) is a hereditary nephropathy characterized by progressive renal failure, hearing loss and ocular lesions. Numerous mutations of the COL4A5 gene encoding the alpha 5-chain of type IV collagen have been described, establishing the molecular cause of AS. The goal of the present study was to identify the genotype-phenotype correlations that are helpful in clinical counseling. COL4A5-mutations (n=267) in males were analysed including 23 German Alport families.
METHODS: Exons of the COL4A5 gene were PCR-amplified and screened by Southern blot, direct sequencing or denaturing gradient gel electrophoresis. Phenotypes were obtained by questionnaires or extracted from 44 publications in the literature. Data were analysed by Kaplan-Meier statistics, chi(2) and Kruskal-Wallis tests.
RESULTS: Genotype-phenotype data for 23 German Alport families are reported. Analysis of these data and of mutations published in the literature showed the type of mutation being a significant predictor of end-stage renal failure (ESRF) age. The patients' renal phenotypes could be grouped into three cohorts: (1) large rearrangements, frame shift, nonsense, and splice donor mutations had a mean ESRF age of 19.8+/-5.7 years; (2) non-glycine- or 3' glycine-missense mutations, in-frame deletions/insertions and splice acceptor mutations had a mean ESRF age of 25.7+/-7.2 years and fewer extrarenal symptoms; (3) 5' glycine substitutions had an even later onset of ESRF at 30.1+/-7.2 years. Glycine-substitutions occurred less commonly de novo than all other mutations (5.5% vs 13.9%). However, due to the evolutionary advantage of their moderate phenotype, they were the most common mutations. The intrafamilial phenotype of an individual mutation was found to be very consistent with regards to the manifestation of deafness, lenticonus and the time point of onset of ESRF.
CONCLUSIONS: Knowledge of the mutation adds significant information about the progress of renal and extrarenal disease in males with X-linked AS. We suggest that the considerable prognostic relevance of a patient's genotype should be included in the classification of the Alport phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105244     DOI: 10.1093/ndt/17.7.1218

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  81 in total

1.  Poststreptococcal acute glomerulonephritis can be a risk factor for accelerating kidney dysfunction in Alport syndrome: a case experience.

Authors:  Yoshinori Araki; Azusa Kawaguchi; Nana Sakakibara; Yoshinobu Nagaoka; Tomohiko Yamamura; Tomoko Horinouchi; China Nagano; Naoya Morisada; Kazumoto Iijima; Kandai Nozu
Journal:  CEN Case Rep       Date:  2020-06-26

2.  Alport syndrome: About time--treating children with Alport syndrome.

Authors:  Judy Savige
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

3.  Genotype-phenotype correlation in X-linked Alport syndrome.

Authors:  Mir Reza Bekheirnia; Berenice Reed; Martin C Gregory; Kim McFann; Alireza Abdollah Shamshirsaz; Amirali Masoumi; Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 10.121

4.  X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene.

Authors:  Xue Jun Fu; Kandai Nozu; Aya Eguchi; Yoshimi Nozu; Naoya Morisada; Akemi Shono; Mariko Taniguchi-Ikeda; Yuko Shima; Koichi Nakanishi; Igor Vorechovsky; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-11-18       Impact factor: 2.801

Review 5.  Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.

Authors:  J Des Parkin; James D San Antonio; Vadim Pedchenko; Billy Hudson; Shane T Jensen; Judy Savige
Journal:  Hum Mutat       Date:  2011-02       Impact factor: 4.878

6.  Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical?

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

7.  Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome.

Authors:  Tomoko Horinouchi; Kandai Nozu; Tomohiko Yamamura; Shogo Minamikawa; Takashi Omori; Keita Nakanishi; Junya Fujimura; Akira Ashida; Mineaki Kitamura; Mitsuhiro Kawano; Wataru Shimabukuro; Chizuko Kitabayashi; Aya Imafuku; Keiichi Tamagaki; Koichi Kamei; Kenjirou Okamoto; Shuichiro Fujinaga; Masafumi Oka; Toru Igarashi; Akinori Miyazono; Emi Sawanobori; Rika Fujimaru; Koichi Nakanishi; Yuko Shima; Masafumi Matsuo; Ming Juan Ye; Yoshimi Nozu; Naoya Morisada; Hiroshi Kaito; Kazumoto Iijima
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 8.  Ocular features in Alport syndrome: pathogenesis and clinical significance.

Authors:  Judy Savige; Shivanand Sheth; Anita Leys; Anjali Nicholson; Heather G Mack; Deb Colville
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-03       Impact factor: 8.237

9.  Identification of a novel COL4A5 mutation in a Chinese family with X-linked Alport syndrome using exome sequencing.

Authors:  Yi Guo; Jinzhong Yuan; Hui Liang; Jingjing Xiao; Hongbo Xu; Lamei Yuan; Kai Gao; Bin Wu; Yongchang Tang; Xiaorong Li; Hao Deng
Journal:  Mol Biol Rep       Date:  2014-02-13       Impact factor: 2.316

10.  Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure.

Authors:  Rachel Tan; Deb Colville; Yan Yan Wang; Lin Rigby; Judy Savige
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.